ACADIA Pharmaceuticals, Inc. (ACAD)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about ACADIA Pharmaceuticals, Inc. (ACAD)
Go deeper and ask any question about ACAD
Company Performance
Current Price
as of Sep 13, 2024$16.32
P/E Ratio
91.43
Market Cap
$2.71B
Description
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Metrics
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerACAD
- Price$16.32+2.32%
Trading Information
- Market Cap$2.71B
- Float99.24%
- Average Daily Volume (1m)1,249,448
- Average Daily Volume (3m)1,763,498
- EPS$0.18
Company
- Revenue$890.53M
- Rev Growth (1yr)46.44%
- Net Income$33.39M
- Gross Margin92.47%
- EBITDA Margin13.64%
- EBITDA$33.01M
- EV$2.26B
- EV/Revenue2.53
- P/E91.43
- P/S3.05
Documents
SEC Filings
Factset Street Account
Earnings Calls
Factset